Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation
Top Cited Papers
Open Access
- 13 September 2010
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 207 (10), 2255-2269
- https://doi.org/10.1084/jem.20100559
Abstract
The role of lymphangiogenesis in inflammation has remained unclear. To investigate the role of lymphatic versus blood vasculature in chronic skin inflammation, we inhibited vascular endothelial growth factor (VEGF) receptor (VEGFR) signaling by function-blocking antibodies in the established keratin 14 (K14)-VEGF-A transgenic (Tg) mouse model of chronic cutaneous inflammation. Although treatment with an anti-VEGFR-2 antibody inhibited skin inflammation, epidermal hyperplasia, inflammatory infiltration, and angiogenesis, systemic inhibition of VEGFR-3, surprisingly, increased inflammatory edema formation and inflammatory cell accumulation despite inhibition of lymphangiogenesis. Importantly, chronic Tg delivery of the lymphangiogenic factor VEGF-C to the skin of K14-VEGF-A mice completely inhibited development of chronic skin inflammation, epidermal hyperplasia and abnormal differentiation, and accumulation of CD8 T cells. Similar results were found after Tg delivery of mouse VEGF-D that only activates VEGFR-3 but not VEGFR-2. Moreover, intracutaneous injection of recombinant VEGF-C156S, which only activates VEGFR-3, significantly reduced inflammation. Although lymphatic drainage was inhibited in chronic skin inflammation, it was enhanced by Tg VEGF-C delivery. Together, these results reveal an unanticipated active role of lymphatic vessels in controlling chronic inflammation. Stimulation of functional lymphangiogenesis via VEGFR-3, in addition to antiangiogenic therapy, might therefore serve as a novel strategy to treat chronic inflammatory disorders of the skin and possibly also other organs.Keywords
This publication has 62 references indexed in Scilit:
- VEGF-A expression by HSV-1–infected cells drives corneal lymphangiogenesisThe Journal of Experimental Medicine, 2009
- Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasisProceedings of the National Academy of Sciences of the United States of America, 2009
- Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritisArthritis & Rheumatism, 2009
- Lymphangiogenesis and cancer metastasisJournal of Cellular and Molecular Medicine, 2009
- Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathwaysNature Genetics, 2009
- Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse EmbryosMolecular and Cellular Biology, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodesBlood, 2007
- Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sproutingThe Journal of Experimental Medicine, 2007
- Increased lymphangiogenesis in joints of mice with inflammatory arthritisArthritis Research & Therapy, 2007